Patents Assigned to OPNA BIO SA
  • Compounds and methods for CD73 modulation and indications therefor
    Patent number: 12202818
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: January 21, 2025
    Assignee: OPNA BIO SA
    Inventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
  • Heterocyclic compounds and uses thereof
    Patent number: 12116365
    Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: October 15, 2024
    Assignee: OPNA BIO SA
    Inventors: Prabha N. Ibrahim, Wayne Spevak, Jiazhong Zhang, Songyuan Shi, Ben Powell, Yan Ma
  • Compounds and methods for CD73 modulation and indications therefor
    Patent number: 11807626
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 7, 2023
    Assignee: Opna Bio SA
    Inventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
  • Combinational drug therapies
    Patent number: 11628176
    Abstract: Disclosed is a method of treating a subject suffering from a cancer, comprising administering to the subject a combination of agents comprising: (a) Compound I: or a pharmaceutically acceptable salt thereof; and (b) one or more inhibitors of the androgen receptor signaling pathway; or (c) one or more PARP inhibitors; wherein the amount of the combination of agents is therapeutically effective in the treatment.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: April 18, 2023
    Assignee: OPNA BIO SA
    Inventors: Ben Powell, Athanasios Tsiatis, Jackie Walling